Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AVROBIO, Inc.
  6. News
  7. Summary
    AVRO   US05455M1009

AVROBIO, INC.

(AVRO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BTIG Downgrades AVROBIO to Neutral From Buy

01/05/2022 | 06:19am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about AVROBIO, INC.
05/16AVROBIO to Present at the H.C. Wainwright Global Investment Conference
BU
05/11Barclays Adjusts AVROBIO's Price Target to $4 from $6, Keeps Overweight Rating
MT
05/10AVROBIO, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/10AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
BU
05/10AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/09AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
05/06AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
05/03AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
BU
04/07AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
04/06AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
More news
Analyst Recommendations on AVROBIO, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -108 M - -
Net cash 2022 82,4 M - -
P/E ratio 2022 -0,35x
Yield 2022 -
Capitalization 33,6 M 33,6 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 122
Free-Float 97,4%
Chart AVROBIO, INC.
Duration : Period :
AVROBIO, Inc. Technical Analysis Chart | AVRO | US05455M1009 | MarketScreener
Technical analysis trends AVROBIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 0,78 $
Average target price 4,86 $
Spread / Average Target 519%
EPS Revisions
Managers and Directors
Geoff MacKay President, Chief Executive Officer & Director
Erik John Ostrowski Chief Financial Officer & Treasurer
Bruce Lee Booth Chairman
Christopher Mason Chief Scientific Officer
Kim Raineri Chief Manufacturing & Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
AVROBIO, INC.-79.62%34
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601